Abstract:Diabetic neuropathy (DN) is a characteristic microvascular complication linked to diabetes. It affects about 50% of those who have this ailment. It has been revealed that Advanced Glycation End Products (AGEs) play a role in the development of diabetic neuropathy. Patients diagnosed with type 2 diabetes (T2DM) have higher quantities of methylglyoxal (MG), particularly harmful precursor of AGEs. One of the numerous defensive mechanisms responsible for MG metabolism and prevention of the generation of AGEs is the glyoxalase system. The cytotoxic byproduct methylglyoxal (MG) is removed by the detoxifying enzyme glyoxalase 1 (GLO1) via converting it to D-lactate, which is not harmful to tissues. This study intends to unveil the role of serum methylglyoxal and glyoxalase 1 on the onset of diabetic peripheral neuropathy (DPN). The present research was designed as a case-control study; including 160 individuals (males and females) aged (30-60) years. The subjects were divided into three groups: group one includes 40 type 2 diabetic patients with peripheral neuropathy, group two includes 40 type 2 diabetic patients without peripheral neuropathy and group three includes 80 apparently healthy as the control. Blood specimens were collected from all patients conducted at the National Diabetes Center, Mustansiriyah University in Baghdad, Iraq. Serum was used to measure glyoxalase 1 and Methylglyoxal levels using Enzyme-Linked Immunosorbent Assay (ELISA) technique. Whole blood with ethylene diamine tetraacetic acid (EDTA) was employed to measure glycated hemoglobin (HbA1c) levels with standard biochemical technique (the CLOVER system). Anthropometric measurements, such as height, weight, BMI and duration of diabetes were assessed. Individuals in control group showed higher serum level of glyoxalase 1 (26.4±4.06 ng/ml) than either patients with DPN (13.61±2.22 ng/ml) or patients with T2DM without peripheral neuropathy (15.25±1.68 ng/ml) with highly significant differences. In contrast, patients with DPN demonstrated higher level of methylglyoxal (29.45±6.06 ng/ ml) than either patients with T2DM without peripheral neuropathy (23.76±5.66 ng/ml) or controls (14.04±4.46 ng/ml) with highly significant differences. In the context of Discrimination between Diabetic Peripheral Neuropathy and Diabetes Mellitus without Peripheral Neuropathy, glyoxalase 1 has an area under curve (AUC) of 0.776, 95% confidence interval [CI] been 0.671-0.882. The test's sensitivity and specificity were 73% and 72%, respectively, at the cut-off value of serum glyoxalase 1 = 13.94 ng/ml. The area under curve for methylglyoxal was 0.758, 95% confidence interval was 0.654-0.863, p < 0.001. The test's sensitivity and specificity were 63% and 70%, respectively; at a cut-off value of serum methylglyoxal = 27.57ng/ml. In the context of discrimination between DPN and controls, the area under curve for glyoxalase 1 was 0.997, 95% confidence interval was 0.992-1.0, p<0.001. Sensitivity and specificity were 99% and 97%, respectively, at a cut-off value of serum glyoxalase 1 = 19.45 ng/ml. The area under curve for methylglyoxal was 0.977, 95% confidence interval was 0.965-0.997, p<0.001. Sensitivity and specificity were 93% and 90%, respectively, at a cut-off value of serum methylglyoxal = 20.81 ng/ml. The findings demonstrated that decreased glyoxalase 1 levels and elevated serum methylglyoxal levels are contributing factors to the development of diabetic peripheral neuropathy in the group of patients under study.

Population genetics of human glyoxalases

Determination of Glyoxalase-1 levels and Identification of Genetic Variants in GLO1 Gene in Patients of Diabetic Nephropathy

Association between GLO1 variants and gestational diabetes mellitus susceptibility in a Chinese population: a preliminary study

Genotype of Ethanol Metabolizing Enzyme Genes by Oligonucleotide Microarray in Alcoholic Liver Disease in Chinese People.

Role for Glyoxalase I in Alzheimer's Disease.

Clinical Implications of Glyoxalase1 Gene Polymorphism and Elevated Levels of the Reactive Metabolite Methylglyoxal in the Susceptibility of Type 2 Diabetes Mellitus in the Patients from Asir and Tabuk Regions of Saudi Arabia

Origin and Spread of the ALDH2 Glu504Lys Allele

Catalytic Efficiencies of Allelic Variants of Human Glutathione S-transferase P1-1 Toward Carcinogenic Anti-Diol Epoxides of Benzo[c]phenanthrene and Benzo[g]chrysene.

Genetic polymorphisms in paraoxonase 1 and G protein-coupled receptor 77, and the risk of glucose-6-phosphate dehydrogenase deficiency in a Saudi population

Frequency and spectrum of glucokinase mutations in an adult Maltese population

Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III

Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in Pakistani population

Glu504Lys Single Nucleotide Polymorphism of Aldehyde Dehydrogenase 2 Gene and the Risk of Human Diseases

GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification

Contribution of Known and Unknown Susceptibility Genes to Early-Onset Diabetes in Scandinavia: Evidence for Heterogeneity.

Molecular Link between Glo-1 Expression and Markers of Hyperglycemia and Oxidative Stress in Vascular Complications of Type 2 Diabetes Mellitus

Exploring Appropriate Reference Intervals and Clinical Decision Limits for Glucose-6-Phosphate Dehydrogenase Activity in Individuals From Guangzhou, China

Molecular Assessment of Methylglyoxal-Induced Toxicity and Therapeutic Approaches in Various Diseases: Exploring the Interplay with the Glyoxalase System

Prevalence of Trehalase Enzymopathy Genetic Determinants in Siberian and Russian Far East Populations

The Role of Serum Methylglyoxal and Glyoxalase 1 on Diabetic Peripheral Neuropathy

Complex Haplotypes of GSTM1 Gene Deletions Harbor Signatures of a Selective Sweep in East Asian Populations